Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery

Elie A. Akl, Lara A. Kahale, Holger J. Schünemann*, Mary Mc Grae McDermott

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations


Clinical Question: In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes? Bottom Line: When used for perioperative thromboprophylaxis, there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.

Original languageEnglish (US)
Pages (from-to)1364-1365
Number of pages2
JournalJAMA - Journal of the American Medical Association
Issue number13
StatePublished - Apr 7 2015


ASJC Scopus subject areas

  • Medicine(all)

Cite this